Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2005

View Archived Issues

ELB-139 exerts potent preclinical activity and is tolerated in humans without tolerance or sedation

Cortagine: A novel CRF1 receptor agonist tested in vivo

In vitro and in vivo activity of GlyT-1 inhibitor PF-03311945

Inhibition of HER-2 cleavage as a novel approach for breast cancer therapy

AEterna Zentaris reports progress in key programs

Cardiome reports Q3 highlights

Novel in vivo data on gaboxadol

Tekes grants funding to BioTie's VAP-1 monoclonal antibody program

AnGes registers ninth case of phase I trial for HGF gene medicine

Chromos Molecular Systems shareholders approve Targeted Molecules acquisition

CardioMetabolics concludes SPA for phase III study of CMI X-11S

Epitan inlicenses Vaniqa for Australia

Cryptome Pharmaceuticals to merge with HealthLinx

Pharmexa to acquire assets from IDM Pharma

Eszopiclone effective in rheumatoid arthritis patients with co-existing insomnia

CCR5 antagonist maraviroc useful as short-term monotherapy for HIV-1 infection

Follow-up results released for GlaxoSmithKline Biologicals malaria vaccine

Inhibitors of MDM2-p53 protein-protein interaction described

Novel P2Y receptor antagonist blocks experimental cirrhosis

Myriad's novel proapoptotic compound enhances anticancer efficacy of ionizing radiation

New synthetic retinoic acid agonist reduces wrinkles without irritating skin

Intranasal approach to preventing P. aeruginosa binding to airway epithelial cells

Palmitoyltransferases as a novel target for oncolytic therapy

Chimeric peptide shown more effective than BNP in dogs

Gene therapy alleviates inflammation in arthritic rats

New treatments for cancer covered in recent patents

Recent Boehringer Ingelheim patents report novel analgesic agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...